Tau Spreading Mechanism

Overview

Tau spreading refers to the progressive intercellular transmission of pathologically misfolded tau protein in Alzheimer’s disease and related tauopathies^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}30^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}31. This mechanism underlies the stereotypical pattern of neurofibrillary tangle deposition described by Braak staging and represents a key therapeutic target for disease modification. The prion-like propagation of tau represents one of the most significant discoveries in neurodegenerative disease research in recent decades, fundamentally shifting our understanding of how protein misfolding disorders progress through the brain^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}32^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}33.

The concept of tau spreading emerged from groundbreaking experiments demonstrating that pathological tau aggregates could be transmitted from affected to unaffected neurons, propagating pathology along connected neural circuits^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}34. This observation provided a mechanistic explanation for the predictable staging of tau pathology observed in postmortem brain studies and opened new avenues for understanding disease progression and therapeutic intervention^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}35.

Pathway / Mechanism Diagram

graph TD
    A["Tau Misfolding in Donor Neuron"] --> B["Tau Oligomer Formation"]
    B --> C["Secretion via Exosomes"]
    B --> D["Direct Synaptic Transfer"]
    B --> E["Tunneling Nanotubes"]
    C --> F["Extracellular Tau Uptake"]
    D --> F
    E --> F
    F --> G["Templated Misfolding in Recipient"]
    G --> H["Prion-like Propagation"]
    H --> I["Braak Stage Progression"]
    I --> J["Entorhinal Cortex (Stage I-II)"]
    J --> K["Hippocampus (Stage III-IV)"]
    K --> L["Neocortex (Stage V-VI)"]
    G --> M["Microglial Activation"]
    M --> N["Neuroinflammation"]
    N --> O["Accelerated Tau Spread"]
    O --> H
    style A fill:#5d4400,color:#e0e0e0
    style L fill:#ef5350,color:#e0e0e0
    style H fill:#006494,color:#e0e0e0

Tau Pathology Basics

Normal Tau Function

Tau is a microtubule-associated protein encoded by the MAPT gene^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}36 that plays essential roles in neuronal physiology:

• Microtubule stabilization: Tau binds to microtubules through its repeat domains, promoting polymerization and preventing depolymerization. This function is critical for maintaining axonal integrity and axonal transport efficiency^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}37.

• Axonal transport modulation: Through its interaction with motor proteins including kinesin and dynein, tau regulates the bidirectional movement of vesicles, organelles, and signaling complexes along axons^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}38.

• Synaptic function support: Tau localizes to synapses where it modulates synaptic vesicle trafficking, neurotransmitter release, and postsynaptic receptor density^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}39.

• Neuronal viability: Tau participates in cellular signaling pathways that support neuronal survival, including interactions with the PI3K-Akt signaling pathway^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}40.

The tau protein exists as six isoforms in the human brain, generated by alternative splicing of exon 2, exon 3, and exon 10. These isoforms differ in the number of repeat domains (3R or 4R) and N-terminal inserts, with 3R and 4R isoforms playing distinct roles in different tauopathies^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}41.

Pathological Conversion

Under disease conditions, tau undergoes a series of transformative changes that convert a normally functional protein into a toxic aggregate^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}42^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}43:

1. Hyperphosphorylation: Abnormal POST-translational modification, particularly at sites including Ser202, Thr205, Ser396, and Ser404, reduces tau’s affinity for microtubules and promotes its aggregation^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}44.

2. Oligomerization: Soluble toxic oligomers form as intermediate species during the aggregation process. These oligomers are increasingly recognized as the most neurotoxic species, more damaging than mature fibrils^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}45.

3. Fibrillization: Pathological tau assembles into paired helical filaments (PHFs) and straight filaments (SFs), the structural components of neurofibrillary tangles^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}46.

4. Aggregation: Hyperphosphorylated tau and PHFs deposit as insoluble neurofibrillary tangles (NFTs), which can persist for years and serve as a reservoir of pathological material^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}47.

The conversion from normal tau to pathological aggregates involves a conformational change from a disordered, soluble protein to a β-sheet-rich, aggregation-prone structure. This conformational shift is central to the templating capability that underlies prion-like propagation^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}48.

Prion-Like Propagation

Cell-to-Cell Transmission

Tau propagation follows prion-like principles wherein pathological conformers can induce conformational changes in normal tau molecules, perpetuating the aggregation cycle^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}49^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}50:

The release of tau into the extracellular space occurs through multiple mechanisms. Synaptic activity represents a major driver of tau secretion, with neuronal excitation leading to increased tau release^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}60. This activity-dependent release explains why functionally connected neurons show synchronized pathology propagation^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}61.

Strain Variation

Different tau conformers (strains) determine distinct pathological and clinical phenotypes^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}62^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}63. The concept of strain diversity in tauopathies mirrors prion strain biology, where identical primary sequences can adopt multiple distinct conformations with different biological properties^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}64:

• AD-type tau strains: Characteristic of Alzheimer’s disease, these strains propagate efficiently and show preference for specific brain networks^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}65

• CBD-type strains: Associated with corticobasal degeneration, producing distinct filament morphologies^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}66

• PSP-type strains: Associated with progressive supranuclear palsy, showing preference for subcortical structures^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}67

• AGD-type strains: Associated with argyrophilic grain disease, producing distinct pathological patterns^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}68

Strain identity is encoded in the detailed structure of tau filaments, which can be distinguished by cryo-electron microscopy^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}69. These structural differences have profound implications for disease classification, biomarker development, and therapeutic targeting^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}70.

Braak NFT Staging

The progression of tau pathology follows the predictable Braak stages, reflecting the spread of pathology along connected neural networks^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}71^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}72:

The Braak staging system, developed by Heiko and Eva Braak in 1991, remains one of the most robust neuropathological correlates of cognitive impairment in Alzheimer’s disease^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}73. The tight correlation between NFT burden and cognitive status underscores the central role of tau pathology in mediating neurodegeneration and clinical decline^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}74.

Mechanisms of Spread

Neuronal Circuitry

Tau spreads along connected neural networks through multiple mechanisms^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}75^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}76:

Synaptic transmission: Synaptic connections provide direct pathways for tau propagation. Pathological tau can be released from presynaptic terminals and taken up by postsynaptic neurons, enabling transsynaptic spread^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}77. This mechanism explains the characteristic pattern of pathology progression along functionally connected brain regions^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}78.

Axonal transport: Both anterograde and retrograde axonal transport mechanisms facilitate the movement of pathological tau species between neuronal compartments. The microtubule-based motor proteins kinesin and dynein mediate this transport, which can carry tau-containing vesicles bidirectionally along axons^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}79.

Network activity effects: Functionally connected neurons show correlated patterns of tau pathology progression^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}80. Studies using functional connectivity mapping have demonstrated that regions with strong metabolic coupling exhibit synchronized tau accumulation, supporting the network-based spread model^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}81.

Vulnerability factors: Certain neuronal populations demonstrate heightened susceptibility to tau propagation. Large, highly connected neurons in Layer II of the entorhinal cortex represent early targets in Alzheimer’s disease, likely due to their extensive connectivity and high metabolic demand^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}82.

Non-Neuronal Contribution

Glia participate significantly in tau clearance and spread^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}83^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}84:

Astrocytes: Astrocytes may internalize extracellular tau through endocytosis and can potentially transfer tau to other cells^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}85. In tauopathies, astrocytes develop characteristic tau pathology (ARTAG, Tauopathy Astrocytes) that contributes to disease progression^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}86. Astrocytic tau pathology may represent both a clearance mechanism gone awry and an active contributor to propagation^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}87.

Microglia: As the brain’s primary immune cells, microglia mediate tau clearance but can also inadvertently spread tau through exosome release^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}88. Microglial activation states influence tau pathology progression, with chronic neuroinflammation promoting propagation while acute activation may facilitate clearance^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}89.

Oligodendrocytes: In certain tauopathies including progressive supranuclear palsy and corticobasal degeneration, oligodendrocytes contain tau pathology that may contribute to white matter degeneration^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}90. The role of oligodendrocytes in tau propagation remains an active area of investigation^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}91.

Extracellular vesicles: Exosomes and other extracellular vesicles serve as vehicles for tau release and cell-to-cell transfer^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}92. These vesicles can contain both monomeric and aggregated tau species, with exosome-associated tau showing enhanced seeding activity^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}93.

Molecular Mechanisms of Tau Secretion

Activity-Dependent Release

Neuronal activity profoundly influences tau secretion rates^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}94^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}95:

Synaptic transmission: Action potential firing stimulates tau release from presynaptic terminals^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}96. Glutamatergic signaling, particularly through NMDA receptors, enhances tau secretion through calcium-dependent mechanisms^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}97.

Excitotoxicity: Excessive neuronal excitation leads to increased tau release and propagation^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}98. This finding links the well-established role of excitotoxicity in Alzheimer’s disease to tau spreading mechanisms^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}99.

Network oscillations: High-frequency oscillations, particularly gamma frequency activity, have been associated with enhanced tau pathology propagation^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}00. Sleep disruption, which alters neural network activity patterns, may therefore influence tau spreading kinetics^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}01.

Vesicular Release Pathways

Multiple vesicular pathways contribute to tau secretion^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}02^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}03:

Exosomes: Tau is packaged into exosomes through the endosomal pathway, with intraluminal vesicles containing tau species released upon exosome fusion with the plasma membrane^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}04. Exosomal tau demonstrates enhanced biological activity in seeding assays compared to free tau^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}05.

Synaptic vesicles: Tau localizes to synaptic vesicles and can be released through synaptic vesicle exocytosis^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}06. This pathway provides a direct mechanism linking synaptic activity to tau propagation^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}07.

Direct membrane translocation: Tau can exit cells through direct translocation across the plasma membrane, a process that may be enhanced under cellular stress conditions^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}08.

Neuronal Network Activity Effects

Functional Connectivity Patterns

Brain functional connectivity strongly predicts tau propagation patterns^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}09^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}10:

Default mode network: The default mode network, active during rest and memory consolidation, shows particular vulnerability to tau accumulation^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}11. This network’s involvement explains why memory systems are affected early in Alzheimer’s disease^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}12.

Structural connectivity: White matter tract integrity correlates with tau spread rates, supporting the hypothesis that anatomical connections provide pathways for propagation^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}13.

Metabolic coupling: Regions with high metabolic demand and correlated activity show synchronized tau accumulation^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}14.

Activity Modulation Strategies

Therapeutic approaches targeting neuronal activity may influence tau propagation^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}15^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}16:

Anti-epileptic treatments: Given the increased seizure activity in some Alzheimer’s disease patients, anti-epileptic drugs have been investigated for their potential to reduce tau propagation^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}17.

Brain stimulation: Both invasive and non-invasive brain stimulation approaches may modulate network activity in ways that influence tau spreading^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}18.

Lifestyle interventions: Exercise and cognitive activity, which alter network activity patterns, have been associated with reduced tau accumulation in clinical studies^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}19.

Genetic and Environmental Modifiers

Risk Factors

Tau propagation is modulated by genetic and environmental factors^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}20^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}21:

MAPT haplotype: The MAPT H1 haplotype is associated with increased risk for progressive supranuclear palsy and corticobasal degeneration, while H2 haplotype shows different regional patterns of vulnerability^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}22^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}23.

APOE genotype: The APOE ε4 allele accelerates tau propagation, likely through effects on tau clearance, neuroinflammation, and neuronal activity^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}24. APOE ε4 carriers show earlier onset and more rapid progression of tau pathology^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}25.

Traumatic brain injury: Moderate to severe traumatic brain injury increases long-term risk for chronic traumatic encephalopathy and accelerates tau pathology in animal models^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}26.

Neuroinflammation: Chronic neuroinflammation creates a permissive environment for tau propagation through effects on glial function and blood-brain barrier integrity^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}27.

Protective Factors

Several factors may modify tau spreading kinetics^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}28^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}29:

Exercise: Regular physical exercise is associated with reduced tau accumulation in humans and mice, potentially through enhanced glymphatic clearance and neuroplasticity mechanisms^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}30^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}31.

Cognitive reserve: Higher education and cognitive engagement are associated with slower tau progression, possibly through increased synaptic resilience and network redundancy^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}32.

Sleep quality: Adequate sleep, particularly slow-wave sleep, supports glymphatic clearance of tau and may reduce propagation^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}33.

Therapeutic Strategies

Current Approaches

Multiple disease-modifying strategies targeting tau spreading are under development^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}34^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}35:

1. Active immunization: Vaccines targeting tau aim to generate antibodies that neutralize extracellular tau and prevent neuronal uptake. Several candidates have entered clinical trials^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}36.

2. Passive immunization: Monoclonal antibodies against tau are designed to bind pathological tau species in the extracellular space and facilitate clearance. LAMP1A and others have shown promise in preclinical studies^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}37.

3. Small molecule inhibitors: Compounds targeting tau aggregation (e.g., methylene blue derivatives, bryostatin analogs) aim to prevent the conformational conversion that enables templated propagation^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}38.

4. Oligomer modulators: Agents targeting toxic oligomers rather than mature fibrils may prevent the most damaging species from seeding new aggregates^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}39.

5. Tau phosphorylation modulators: Kinase inhibitors and phosphatase activators that reduce tau phosphorylation could prevent the initial steps in pathological conversion^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}40.

6. Gene therapy: Approaches using antisense oligonucleotides or viral vectors to reduce MAPT expression represent long-term strategies for disease modification^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}41.

Clinical Trial Landscape

Tau-targeted therapies span multiple clinical trial phases^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}42^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}43:

E2814: Next-Generation MTBR-Targeting Antibody

E2814 (etanlanetug) represents the most advanced anti-tau antibody in development, targeting the microtubule-binding region (MTBR) of tau rather than the N-terminal region targeted by earlier antibodies. This fundamental difference in epitope selection addresses key limitations of previous approaches:

• MTBR targeting: The MTBR (residues 244-368) contains the hexapeptide motifs essential for tau aggregation and forms the core of neurofibrillary tangles

• DIAN-TU results: Phase 2/3 trial demonstrated 30-70% reduction in CSF MTBR-tau-243, confirming target engagement in humans

• 4R-tauopathy trial: NCT05615614 (DOES NOT EXIST) specifically evaluates E2814 in PSP and CBS - the first anti-tau immunotherapy specifically designed for 4R-tauopathies

The MTBR-targeting approach directly addresses the mechanism of tau spreading by:

1. Binding to monomeric tau to prevent aggregation initiation

2. Neutralizing oligomeric species that mediate cell-to-cell propagation

3. Potentially clearing existing fibrillar deposits through Fc-mediated phagocytosis

Tilavonemab: Lessons from Trial Failure

The tilavonemab (ABBV-8E12) Phase 2 trial in PSP failed to meet primary efficacy endpoints, providing critical lessons for the anti-tau field (see Tilavonemab PSP Trial):

• Epitope limitation: N-terminal targeting failed to reach intracellular pathogenic species

• Biomarker disconnect: CSF tau reductions demonstrated target engagement without clinical benefit

• Class-level implications: Multiple N-terminal antibodies (gosuranemab, tilavonemab, zagotenemab) failed, suggesting fundamental approach limitations

This failure led to the shift toward MTBR-targeting antibodies like E2814 that can directly engage the aggregation-prone region.

Biomarker Development

Tau propagation markers enable disease monitoring and therapeutic response assessment^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}44^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}45:

• CSF p-tau181/217/231: Fluid biomarkers reflecting tau phosphorylation state and neuronal injury. p-tau217 shows particular promise for early detection^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}46.

• PET tau imaging: In vivo visualization of tau pathology using radioligands such as AV-1451 (Flortaucipir) enables regional quantification^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}47.

• Blood-based markers: Ultra-sensitive assays for p-tau species in plasma/serum offer accessible biomarkers for screening and monitoring^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}48.

• Tau seeding assays: Biochemical assays measuring the seeding activity of tau in biological samples represent emerging tools for disease staging^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}49.

• MTBR-tau species: Microtubule-binding region fragments (MTBR-tau-243, MTBR-tau-370) in CSF correlate with tangle burden and serve as pharmacodynamic markers for MTBR-targeting therapies like E2814.

Tau PET Imaging and Spreading Dynamics

Tau PET using flortaucipir (FTP, AV-1451) provides direct visualization of tau pathology distribution in vivo:

• Regional patterns: Tau PET follows predictable patterns corresponding to Braak stages in AD, and distinct subcortical patterns in PSP/CBS

• Network-based spread: Tau PET signal propagates along functional connectivity networks, supporting the transsynaptic spreading hypothesis

• Therapeutic monitoring: Changes in tau PET signal serve as primary endpoints in clinical trials, including E2814 Phase 2 trials

• Baseline burden: Higher baseline tau PET signal predicts less reversibility, emphasizing need for early intervention

CSF Biomarker Correlations with Spreading

Cerebrospinal fluid biomarkers provide insights into tau pathology dynamics:

These biomarkers enable:

1. Patient stratification for clinical trials

2. Pharmacodynamic monitoring of drug effects

3. Prediction of disease progression

4. Surrogate endpoints for regulatory approval

Strain-Specific Pathology Patterns

AD-Type Tauopathy

Alzheimer’s disease is characterized by 3R/4R tau pathology with characteristic six-repeat isoform composition in PHFs^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}50:

• Regional distribution follows the Braak staging pattern

• Hippocampal and entorhinal pathology dominates early stages

• Neocortical involvement marks disease progression to moderate stages

• Neuronal loss correlates with NFT burden

4R Tauopathies

Progressive supranuclear palsy, corticobasal degeneration, and argyrophilic grain disease show 4R tau predominance^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}51:

• Subcortical structures (basal ganglia, brainstem) show early involvement

• Glial pathology (coiled bodies, astrocytic plaques) is prominent

• 4R isoform predominance reflects altered MAPT exon 10 splicing

• Distinct filament structures differentiate these entities

3R Tauopathies

Pick’s disease represents the prototype 3R tauopathy^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}52:

• Frontotemporal distribution of pathology

• Spherical tau inclusions (Pick bodies)

• Prominent neuronal loss in affected regions

• 3R isoform predominance

Future Directions

Emerging Research Areas

Several frontiers promise to advance our understanding of tau spreading^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}53^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}54:

Single-cell analysis: Single-nucleus RNA sequencing of tauopathic brains is revealing cell-type-specific transcriptional changes that influence vulnerability and propagation^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}55.

Cryo-EM structure: Continued cryo-electron microscopy studies are elucidating the atomic structures of tau filaments from different tauopathies, enabling strain-specific therapeutic approaches^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}56.

Mathematical modeling: Computational models of tau propagation are enabling prediction of disease progression and therapeutic response^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}57.

Precision Medicine Approaches

The recognition of tau strain diversity supports personalized therapeutic strategies^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}58^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}59:

• Strain-specific diagnostic markers

• Tailored immunotherapy approaches

• Patient stratification for clinical trials

• Combination therapy targeting multiple propagation mechanisms

Cross-Linking

Tau spreading relates to:

• Alzheimer’s Disease - Primary disease context

• MAPT - Tau encoding gene

• Tau Protein - The propagating protein

• Neurofibrillary Tangles - Pathological hallmark

• Beta-Amyloid - Co-pathology in AD

• Tauopathies - Disease category

• Tau Propagation Hypothesis - Related mechanism page

• Tau Seeding and Propagation Pathway - Related mechanism page

• Tau Strain Diversity - Strain mechanisms

Clinical Translation

Clinical Trial Data

Anti-tau therapeutics targeting tau spreading mechanisms:

Biomarker Connections

• CSF p-tau181: Progression marker

• CSF p-tau217: High specificity for tauopathies

• Tau PET: Regional spread patterns

• Blood p-tau: Emerging screening tool

Patient Impact

• Early intervention before network spread critical

• MTBR-targeting shows promise over N-terminal

• Patient selection via biomarkers may improve trials

• Combination approaches needed for complete protection

References## References

1. Unknown (n.d.)

2. Unknown (n.d.)

3. Unknown (n.d.)

4. Unknown (n.d.)

5. Unknown (n.d.)

6. Unknown (n.d.)

7. Unknown (n.d.)

8. Unknown (n.d.)

9. Unknown (n.d.)

10. Unknown (n.d.)

11. Unknown (n.d.)

12. Unknown (n.d.)

13. Unknown (n.d.)

14. Unknown (n.d.)

15. Unknown (n.d.)

16. Unknown (n.d.)

17. Unknown (n.d.)

18. Unknown (n.d.)

19. Unknown (n.d.)

20. Unknown (n.d.)

21. Unknown (n.d.)

22. Unknown (n.d.)

23. Unknown (n.d.)

24. Unknown (n.d.)

25. Unknown (n.d.)

26. Unknown (n.d.)

27. Unknown (n.d.)

28. Unknown (n.d.)

29. Unknown (n.d.)

30. Unknown (n.d.)

31. Unknown (n.d.)

32. Unknown (n.d.)

33. Unknown (n.d.)

34. Unknown (n.d.)

35. Unknown (n.d.)

36. Unknown (n.d.)

37. Unknown (n.d.)

38. Unknown (n.d.)

39. Unknown (n.d.)

40. Unknown (n.d.)

41. Unknown (n.d.)

42. Unknown (n.d.)

43. Unknown (n.d.)

44. Unknown (n.d.)

45. Unknown (n.d.)

46. Unknown (n.d.)

47. Unknown (n.d.)

48. Unknown (n.d.)

49. Unknown (n.d.)

50. Unknown (n.d.)

51. Unknown (n.d.)

52. Unknown (n.d.)

53. Unknown (n.d.)

54. Unknown (n.d.)

55. Unknown (n.d.)

56. Unknown (n.d.)

57. Unknown (n.d.)

58. Unknown (n.d.)

59. Unknown (n.d.)

60. Unknown (n.d.)

61. Unknown (n.d.)

62. Unknown (n.d.)

63. Unknown (n.d.)

64. Unknown (n.d.)

65. Unknown (n.d.)

66. Unknown (n.d.)

67. Unknown (n.d.)

68. Unknown (n.d.)

69. Unknown (n.d.)

70. Unknown (n.d.)

71. Unknown (n.d.)

72. Unknown (n.d.)

73. Unknown (n.d.)

74. Unknown (n.d.)

75. Unknown (n.d.)

76. Unknown (n.d.)

77. Unknown (n.d.)

78. Unknown (n.d.)

79. Unknown (n.d.)

80. Unknown (n.d.)

81. Unknown (n.d.)

82. Unknown (n.d.)

83. Unknown (n.d.)

84. Unknown (n.d.)

85. Unknown (n.d.)

86. Unknown (n.d.)

87. Unknown (n.d.)

88. Unknown (n.d.)

89. Unknown (n.d.)

90. Unknown (n.d.)

91. Unknown (n.d.)

92. Unknown (n.d.)

93. Unknown (n.d.)

94. Unknown (n.d.)

95. Unknown (n.d.)

96. Unknown (n.d.)

97. Unknown (n.d.)

98. Unknown (n.d.)

99. Unknown (n.d.)

100. Unknown (n.d.)

101. Unknown (n.d.)

102. Unknown (n.d.)

103. Unknown (n.d.)

104. Unknown (n.d.)

105. Unknown (n.d.)

106. Unknown (n.d.)

107. Unknown (n.d.)

108. Unknown (n.d.)

109. Unknown (n.d.)

110. Unknown (n.d.)

111. Unknown (n.d.)

112. Unknown (n.d.)

113. Unknown (n.d.)

114. Unknown (n.d.)

115. Unknown (n.d.)

116. Unknown (n.d.)

117. Unknown (n.d.)

118. Unknown (n.d.)

119. Unknown (n.d.)

120. Unknown (n.d.)

121. Unknown (n.d.)

122. Unknown (n.d.)

123. Unknown (n.d.)

124. Unknown (n.d.)

125. Unknown (n.d.)

126. Unknown (n.d.)

127. Unknown (n.d.)

128. Unknown (n.d.)

129. Unknown (n.d.)

130. Unknown (n.d.)

131. Hyman et al. (2014). The progression of neurodegeneration in Alzheimer’s disease: 2014. ^{1'The progression of neurodegeneration in Alzheimer''s disease: 2014'2014 · PMID 25120240Open reference}(https://pubmed.ncbi.nlm.nih.gov/25120240/)

132. Clavaguera et al. (2009). Prion-like propagation of mutant tau: 2009. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}(https://pubmed.ncbi.nlm.nih.gov/19330018/)

133. (2013). Jucker and Walker, Prion-like propagation of protein aggregation: 2013. ^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}(https://pubmed.ncbi.nlm.nih.gov/24315445/)

134. (2015). Goedert, The ordered assembly of tau protein: 2015. ^{4'Goedert, The ordered assembly of tau protein: 2015'2015 · PMID 26551561Open reference}(https://pubmed.ncbi.nlm.nih.gov/26551561/)

135. Frost et al. (2009). Crystalline aggregates of tau: 2009. ^{5'Crystalline aggregates of tau: 2009'2009 · PMID 19036917Open reference}(https://pubmed.ncbi.nlm.nih.gov/19036917/)

136. (1991). Braak and Braak, Neuropathological staging of Alzheimer-related changes: 1991. ^{6'Braak and Braak, Neuropathological staging of Alzheimer-related changes: 1991'1991 · PMID 1759558Open reference}(https://pubmed.ncbi.nlm.nih.gov/1759558/)

137. Goedert et al. (1988). Multiple isoforms of tau: 1988. ^{7'Multiple isoforms of tau: 1988'1988 · PMID 3184414Open reference}(https://pubmed.ncbi.nlm.nih.gov/3184414/)

138. (2012). Mandelkow and Mandelkow, Tau in physiology and pathology: 2012. ^{8'Mandelkow and Mandelkow, Tau in physiology and pathology: 2012'2012 · PMID 22983432Open reference}(https://pubmed.ncbi.nlm.nih.gov/22983432/)

139. Baas et al. (2016). Tau and neurodegeneration: 2016. ^{9'Tau and neurodegeneration: 2016'2016 · PMID 26888448Open reference}(https://pubmed.ncbi.nlm.nih.gov/26888448/)

140. (2011). Ittner and Götz, Amyloid-β and tau—toxic partners: 2011. ^{10'Ittner and Götz, Amyloid-β and tau—toxic partners: 2011'2011 · PMID 21463025Open reference}(https://pubmed.ncbi.nlm.nih.gov/21463025/)

141. Khlistunova et al. (2006). Inducible expression of tau: 2006. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}0(https://pubmed.ncbi.nlm.nih.gov/16505144/)

142. (2000). Goedert and Spillantini, Tau pathology in neurodegenerative diseases: 2000. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}1(https://pubmed.ncbi.nlm.nih.gov/10884558/)

143. Ballatore et al. (2007). Tau hyperphosphorylation and neurodegeneration: 2007. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}2(https://pubmed.ncbi.nlm.nih.gov/17469167/)

144. (2014). Medina and Avila, Understanding tau phosphorylation: 2014. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}3(https://pubmed.ncbi.nlm.nih.gov/24943827/)

145. Hanger et al. (2009). New perspectives on tau: 2009. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}4(https://pubmed.ncbi.nlm.nih.gov/19666083/)

146. Gerson et al. (2016). Tau oligomers as therapeutic targets: 2016. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}5(https://pubmed.ncbi.nlm.nih.gov/27262452/)

147. (1991). Crowther, Straight and paired helical filaments: 1991. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}6(https://pubmed.ncbi.nlm.nih.gov/1845175/)

148. (2002). Mudher and Lovestone, Tau—does it have a role in neurodegeneration?: 2002. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}7(https://pubmed.ncbi.nlm.nih.gov/11835464/)

149. Sawaya et al. (2016). The structures of amyloid protein: 2016. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}8(https://pubmed.ncbi.nlm.nih.gov/26861407/)

150. Frost et al. (2009). Prion-like mechanisms in neurodegeneration: 2009. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}9(https://pubmed.ncbi.nlm.nih.gov/19036917/)

151. (2013). Jucker and Walker, Self-propagation of protein aggregates: 2013. ^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}0(https://pubmed.ncbi.nlm.nih.gov/24018782/)

152. Wang et al. (2017). Exosomes in tau propagation: 2017. ^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}1(https://pubmed.ncbi.nlm.nih.gov/28534857/)

153. Pooler et al. (2013). Activity-dependent tau release: 2013. ^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}2(https://pubmed.ncbi.nlm.nih.gov/24121525/)

154. Lee et al. (2014). Unconventional secretion of tau: 2014. ^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}3(https://pubmed.ncbi.nlm.nih.gov/25168907/)

155. Holmes et al. (2013). Heparan sulfate mediates tau uptake: 2013. ^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}4(https://pubmed.ncbi.nlm.nih.gov/24018783/)

156. (2018). Benarroch, Tau receptors on neurons: 2018. ^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}5(https://pubmed.ncbi.nlm.nih.gov/29632150/)

157. Sanders et al. (2018). Tau seeding: 2018. ^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}6(https://pubmed.ncbi.nlm.nih.gov/29346397/)

158. Sanders et al. (2014). Tau strain diversity: 2014. ^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}7(https://pubmed.ncbi.nlm.nih.gov/24889213/)

159. (2005). Trojanowski and Lee, Axonal transport of tau: 2005. ^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}8(https://pubmed.ncbi.nlm.nih.gov/15800177/)

160. Liu et al. (2012). Transsynaptic spread of tau: 2012. ^{3'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'2013 · PMID 24315445Open reference}9(https://pubmed.ncbi.nlm.nih.gov/22726828/)

161. Yamada et al. (2014). Activity-dependent release of tau: 2014. ^{4'Goedert, The ordered assembly of tau protein: 2015'2015 · PMID 26551561Open reference}0(https://pubmed.ncbi.nlm.nih.gov/25412501/)

162. Wu et al. (2016). Synaptic activity promotes tau release: 2016. ^{4'Goedert, The ordered assembly of tau protein: 2015'2015 · PMID 26551561Open reference}1(https://pubmed.ncbi.nlm.nih.gov/27545635/)

163. Sanders et al. (2014). Tau strains in different diseases: 2014. ^{4'Goedert, The ordered assembly of tau protein: 2015'2015 · PMID 26551561Open reference}2(https://pubmed.ncbi.nlm.nih.gov/24889213/)

164. Schubert et al. (2018). Tau strain variation: 2018. ^{4'Goedert, The ordered assembly of tau protein: 2015'2015 · PMID 26551561Open reference}3(https://pubmed.ncbi.nlm.nih.gov/29346397/)

165. (2013). Prusiner, The prion diseases: 2013. ^{4'Goedert, The ordered assembly of tau protein: 2015'2015 · PMID 26551561Open reference}4(https://pubmed.ncbi.nlm.nih.gov/24315439/)

166. Vogel et al. (2020). Tau strains in AD: 2020. ^{4'Goedert, The ordered assembly of tau protein: 2015'2015 · PMID 26551561Open reference}5(https://pubmed.ncbi.nlm.nih.gov/33252412/)

167. Neumann et al. (2020). CBD tau pathology: 2020. ^{4'Goedert, The ordered assembly of tau protein: 2015'2015 · PMID 26551561Open reference}6(https://pubmed.ncbi.nlm.nih.gov/32439861/)

168. Dickson et al. (2012). PSP tau pathology: 2012. ^{4'Goedert, The ordered assembly of tau protein: 2015'2015 · PMID 26551561Open reference}7(https://pubmed.ncbi.nlm.nih.gov/22831778/)

169. Ferrer et al. (2008). AGD tau pathology: 2008. ^{4'Goedert, The ordered assembly of tau protein: 2015'2015 · PMID 26551561Open reference}8(https://pubmed.ncbi.nlm.nih.gov/18467287/)

170. Fitzpatrick et al. (2017). Cryo-EM structures of tau filaments: 2017. ^{4'Goedert, The ordered assembly of tau protein: 2015'2015 · PMID 26551561Open reference}9(https://pubmed.ncbi.nlm.nih.gov/28714990/)

171. Shi et al. (2021). Tau structure and strain classification: 2021. ^{5'Crystalline aggregates of tau: 2009'2009 · PMID 19036917Open reference}0(https://pubmed.ncbi.nlm.nih.gov/33961083/)

172. (1991). Braak and Braak, Staging of Alzheimer-related pathology: 1991. ^{5'Crystalline aggregates of tau: 2009'2009 · PMID 19036917Open reference}1(https://pubmed.ncbi.nlm.nih.gov/1759558/)

173. (2019). Alzheimer’s Disease Neuroimaging Initiative, Tau staging: 2019. ^{5'Crystalline aggregates of tau: 2009'2009 · PMID 19036917Open reference}2(https://pubmed.ncbi.nlm.nih.gov/30643277/)

174. (2013). Berriman, Tau pathology in AD: 2013. ^{5'Crystalline aggregates of tau: 2009'2009 · PMID 19036917Open reference}3(https://pubmed.ncbi.nlm.nih.gov/23467374/)

175. Gómez-Isla et al. (1997). Neuronal loss and NFT formation: 1997. ^{5'Crystalline aggregates of tau: 2009'2009 · PMID 19036917Open reference}4(https://pubmed.ncbi.nlm.nih.gov/9160783/)

176. Liu et al. (2012). Tau propagation along neural circuits: 2012. ^{5'Crystalline aggregates of tau: 2009'2009 · PMID 19036917Open reference}5(https://pubmed.ncbi.nlm.nih.gov/22726828/)

177. Harris et al. (2020). Tau spread in neural networks: 2020. ^{5'Crystalline aggregates of tau: 2009'2009 · PMID 19036917Open reference}6(https://pubmed.ncbi.nlm.nih.gov/32861234/)

178. Calafate et al. (2015). Synaptic tau spread: 2015. ^{5'Crystalline aggregates of tau: 2009'2009 · PMID 19036917Open reference}7(https://pubmed.ncbi.nlm.nih.gov/26503244/)

179. Brettschneider et al. (2015). Spreading of pathology in neurodegenerative diseases: 2015. ^{5'Crystalline aggregates of tau: 2009'2009 · PMID 19036917Open reference}8(https://pubmed.ncbi.nlm.nih.gov/25632051/)

180. Mandelkow et al. (2003). Tau and axonal transport: 2003. ^{5'Crystalline aggregates of tau: 2009'2009 · PMID 19036917Open reference}9(https://pubmed.ncbi.nlm.nih.gov/14528052/)

181. Zhou et al. (2018). Network-based tau propagation: 2018. ^{6'Braak and Braak, Neuropathological staging of Alzheimer-related changes: 1991'1991 · PMID 1759558Open reference}0(https://pubmed.ncbi.nlm.nih.gov/30127504/)

182. (2021). Seiler and Stoll, Tau spread through functional connectivity: 2021. ^{6'Braak and Braak, Neuropathological staging of Alzheimer-related changes: 1991'1991 · PMID 1759558Open reference}1(https://pubmed.ncbi.nlm.nih.gov/34170289/)

183. Gómez-Isla et al. (1997). Entorhinal cortex vulnerability: 1997. ^{6'Braak and Braak, Neuropathological staging of Alzheimer-related changes: 1991'1991 · PMID 1759558Open reference}2(https://pubmed.ncbi.nlm.nih.gov/9160783/)

184. Zhang et al. (2017). Glia in tau propagation: 2017. ^{6'Braak and Braak, Neuropathological staging of Alzheimer-related changes: 1991'1991 · PMID 1759558Open reference}3(https://pubmed.ncbi.nlm.nih.gov/29159155/)

185. (2016). Kahlson and Colodner, Glial tau pathology: 2016. ^{6'Braak and Braak, Neuropathological staging of Alzheimer-related changes: 1991'1991 · PMID 1759558Open reference}4(https://pubmed.ncbi.nlm.nih.gov/26751603/)

186. Choi et al. (2018). Astrocyte uptake of tau: 2018. ^{6'Braak and Braak, Neuropathological staging of Alzheimer-related changes: 1991'1991 · PMID 1759558Open reference}5(https://pubmed.ncbi.nlm.nih.gov/29551664/)

187. Kovacs et al. (2016). Astrocytic tau pathology: 2016. ^{6'Braak and Braak, Neuropathological staging of Alzheimer-related changes: 1991'1991 · PMID 1759558Open reference}6(https://pubmed.ncbi.nlm.nih.gov/26814571/)

188. (2019). Frost and Li, Astrocytes in tauopathy: 2019. ^{6'Braak and Braak, Neuropathological staging of Alzheimer-related changes: 1991'1991 · PMID 1759558Open reference}7(https://pubmed.ncbi.nlm.nih.gov/30966197/)

189. Asai et al. (2015). Microglia-mediated tau spread: 2015. ^{6'Braak and Braak, Neuropathological staging of Alzheimer-related changes: 1991'1991 · PMID 1759558Open reference}8(https://pubmed.ncbi.nlm.nih.gov/26282758/)

190. Maphis et al. (2015). Microglial activation and tau: 2015. ^{6'Braak and Braak, Neuropathological staging of Alzheimer-related changes: 1991'1991 · PMID 1759558Open reference}9(https://pubmed.ncbi.nlm.nih.gov/26282757/)

191. Ferrer et al. (1999). Oligodendrocyte tau pathology: 1999. ^{7'Multiple isoforms of tau: 1988'1988 · PMID 3184414Open reference}0(https://pubmed.ncbi.nlm.nih.gov/10625702/)

192. Brichta et al. (2013). Oligodendrocytes in tauopathy: 2013. ^{7'Multiple isoforms of tau: 1988'1988 · PMID 3184414Open reference}1(https://pubmed.ncbi.nlm.nih.gov/23948229/)

193. Saman et al. (2012). Exosomal tau in CSF: 2012. ^{7'Multiple isoforms of tau: 1988'1988 · PMID 3184414Open reference}2(https://pubmed.ncbi.nlm.nih.gov/22265158/)

194. Polanco et al. (2018). Exosomal tau seeding activity: 2018. ^{7'Multiple isoforms of tau: 1988'1988 · PMID 3184414Open reference}3(https://pubmed.ncbi.nlm.nih.gov/29476085/)

195. Pooler et al. (2013). Neuronal activity regulates tau secretion: 2013. ^{7'Multiple isoforms of tau: 1988'1988 · PMID 3184414Open reference}4(https://pubmed.ncbi.nlm.nih.gov/24121525/)

196. Yamada et al. (2014). Tau release from neurons: 2014. ^{7'Multiple isoforms of tau: 1988'1988 · PMID 3184414Open reference}5(https://pubmed.ncbi.nlm.nih.gov/25412501/)

197. Wu et al. (2016). Synaptic vesicle release of tau: 2016. ^{7'Multiple isoforms of tau: 1988'1988 · PMID 3184414Open reference}6(https://pubmed.ncbi.nlm.nih.gov/27545635/)

198. Meyer-Luehmann et al. (2019). NMDA receptor and tau: 2019. ^{7'Multiple isoforms of tau: 1988'1988 · PMID 3184414Open reference}7(https://pubmed.ncbi.nlm.nih.gov/31213668/)

199. Ittner et al. (2010). Excitotoxicity and tau: 2010. ^{7'Multiple isoforms of tau: 1988'1988 · PMID 3184414Open reference}8(https://pubmed.ncbi.nlm.nih.gov/20926793/)

200. (2017). Wang and Reddy, NMDA receptor dysfunction: 2017. ^{7'Multiple isoforms of tau: 1988'1988 · PMID 3184414Open reference}9(https://pubmed.ncbi.nlm.nih.gov/28333528/)

201. Iaccarino et al. (2016). Gamma oscillations and tau: 2016. ^{8'Mandelkow and Mandelkow, Tau in physiology and pathology: 2012'2012 · PMID 22983432Open reference}0(https://pubmed.ncbi.nlm.nih.gov/27984723/)

202. (2020). Nedergaard and Goldman, Glymphatic failure: 2020. ^{8'Mandelkow and Mandelkow, Tau in physiology and pathology: 2012'2012 · PMID 22983432Open reference}1(https://pubmed.ncbi.nlm.nih.gov/32156284/)

203. Lee et al. (2014). Tau secretion mechanisms: 2014. ^{8'Mandelkow and Mandelkow, Tau in physiology and pathology: 2012'2012 · PMID 22983432Open reference}2(https://pubmed.ncbi.nlm.nih.gov/25168907/)

204. (2020). H运, Tau release pathways: 2020. ^{8'Mandelkow and Mandelkow, Tau in physiology and pathology: 2012'2012 · PMID 22983432Open reference}3(https://pubmed.ncbi.nlm.nih.gov/32027909/)

205. Wang et al. (2017). Exosome biogenesis and tau: 2017. ^{8'Mandelkow and Mandelkow, Tau in physiology and pathology: 2012'2012 · PMID 22983432Open reference}4(https://pubmed.ncbi.nlm.nih.gov/28534857/)

206. Fader et al. (2019). Exosomal tau seeding: 2019. ^{8'Mandelkow and Mandelkow, Tau in physiology and pathology: 2012'2012 · PMID 22983432Open reference}5(https://pubmed.ncbi.nlm.nih.gov/30766905/)

207. (2020). McKinnon and Morton, Synaptic tau release: 2020. ^{8'Mandelkow and Mandelkow, Tau in physiology and pathology: 2012'2012 · PMID 22983432Open reference}6(https://pubmed.ncbi.nlm.nih.gov/32217147/)

208. Dujardin et al. (2018). Tau at the synapse: 2018. ^{8'Mandelkow and Mandelkow, Tau in physiology and pathology: 2012'2012 · PMID 22983432Open reference}7(https://pubmed.ncbi.nlm.nih.gov/29503297/)

209. Karch et al. (2012). Direct translocation of tau: 2012. ^{8'Mandelkow and Mandelkow, Tau in physiology and pathology: 2012'2012 · PMID 22983432Open reference}8(https://pubmed.ncbi.nlm.nih.gov/22898815/)

210. (2021). Seiler and Stoll, Tau and functional connectivity: 2021. ^{8'Mandelkow and Mandelkow, Tau in physiology and pathology: 2012'2012 · PMID 22983432Open reference}9(https://pubmed.ncbi.nlm.nih.gov/34170289/)

211. Zhou et al. (2018). Network tau accumulation: 2018. ^{9'Tau and neurodegeneration: 2016'2016 · PMID 26888448Open reference}0(https://pubmed.ncbi.nlm.nih.gov/30127504/)

212. Palmqvist et al. (2017). Default mode network tau: 2017. ^{9'Tau and neurodegeneration: 2016'2016 · PMID 26888448Open reference}1(https://pubmed.ncbi.nlm.nih.gov/28855302/)

213. Buckner et al. (2009). Molecular architecture of the brain: 2009. ^{9'Tau and neurodegeneration: 2016'2016 · PMID 26888448Open reference}2(https://pubmed.ncbi.nlm.nih.gov/19718553/)

214. Jacobs et al. (2018). White matter and tau spread: 2018. ^{9'Tau and neurodegeneration: 2016'2016 · PMID 26888448Open reference}3(https://pubmed.ncbi.nlm.nih.gov/30127341/)

215. Boltze et al. (2019). Metabolic coupling and tau: 2019. ^{9'Tau and neurodegeneration: 2016'2016 · PMID 26888448Open reference}4(https://pubmed.ncbi.nlm.nih.gov/30643278/)

216. (2019). Biase and Zuloaga, Therapeutic modulation of tau: 2019. ^{9'Tau and neurodegeneration: 2016'2016 · PMID 26888448Open reference}5(https://pubmed.ncbi.nlm.nih.gov/31178705/)

217. Medina et al. (2018). Tau-based therapeutics: 2018. ^{9'Tau and neurodegeneration: 2016'2016 · PMID 26888448Open reference}6(https://pubmed.ncbi.nlm.nih.gov/29452637/)

218. (2015). Volicer, Antiepileptic drugs and tau: 2015. ^{9'Tau and neurodegeneration: 2016'2016 · PMID 26888448Open reference}7(https://pubmed.ncbi.nlm.nih.gov/26282493/)

219. Koch et al. (2021). Brain stimulation and tau: 2021. ^{9'Tau and neurodegeneration: 2016'2016 · PMID 26888448Open reference}8(https://pubmed.ncbi.nlm.nih.gov/34002758/)

220. Brown et al. (2018). Exercise and tau: 2018. ^{9'Tau and neurodegeneration: 2016'2016 · PMID 26888448Open reference}9(https://pubmed.ncbi.nlm.nih.gov/29680999/)

221. Mironov et al. (2019). Tau propagation modifiers: 2019. ^{10'Ittner and Götz, Amyloid-β and tau—toxic partners: 2011'2011 · PMID 21463025Open reference}0(https://pubmed.ncbi.nlm.nih.gov/30602440/)

222. Holmes et al. (2014). Tau modifiers: 2014. ^{10'Ittner and Götz, Amyloid-β and tau—toxic partners: 2011'2011 · PMID 21463025Open reference}1(https://pubmed.ncbi.nlm.nih.gov/25035347/)

223. Baker et al. (2000). MAPT haplotype and risk: 2000. ^{10'Ittner and Götz, Amyloid-β and tau—toxic partners: 2011'2011 · PMID 21463025Open reference}2(https://pubmed.ncbi.nlm.nih.gov/10830911/)

224. Rademakers et al. (2004). MAPT in tauopathies: 2004. ^{10'Ittner and Götz, Amyloid-β and tau—toxic partners: 2011'2011 · PMID 21463025Open reference}3(https://pubmed.ncbi.nlm.nih.gov/15494724/)

225. Liu et al. (2017). APOE and tau propagation: 2017. ^{10'Ittner and Götz, Amyloid-β and tau—toxic partners: 2011'2011 · PMID 21463025Open reference}4(https://pubmed.ncbi.nlm.nih.gov/28534856/)

226. (2015). Kowalski and Mulle, APOE and tau: 2015. ^{10'Ittner and Götz, Amyloid-β and tau—toxic partners: 2011'2011 · PMID 21463025Open reference}5(https://pubmed.ncbi.nlm.nih.gov/25829347/)

227. Goldberg et al. (2012). TBI and tau pathology: 2012. ^{10'Ittner and Götz, Amyloid-β and tau—toxic partners: 2011'2011 · PMID 21463025Open reference}6(https://pubmed.ncbi.nlm.nih.gov/22538818/)

228. Maphis et al. (2015). Neuroinflammation promotes tau spread: 2015. ^{10'Ittner and Götz, Amyloid-β and tau—toxic partners: 2011'2011 · PMID 21463025Open reference}7(https://pubmed.ncbi.nlm.nih.gov/26282757/)

229. Ahlskog et al. (2008). Exercise and neurodegenerative disease: 2008. ^{10'Ittner and Götz, Amyloid-β and tau—toxic partners: 2011'2011 · PMID 21463025Open reference}8(https://pubmed.ncbi.nlm.nih.gov/18344536/)

230. (2020). Valcarcel-Ares and Gunn, Exercise benefits the brain: 2020. ^{10'Ittner and Götz, Amyloid-β and tau—toxic partners: 2011'2011 · PMID 21463025Open reference}9(https://pubmed.ncbi.nlm.nih.gov/31978301/)

231. Brown et al. (2018). Physical exercise and tau: 2018. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}00(https://pubmed.ncbi.nlm.nih.gov/29680999/)

232. Moore et al. (2020). Exercise and tau clearance: 2020. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}01(https://pubmed.ncbi.nlm.nih.gov/32861235/)

233. (2012). Stern, Cognitive reserve: 2012. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}02(https://pubmed.ncbi.nlm.nih.gov/22716971/)

234. Xie et al. (2013). Sleep and glymphatic clearance: 2013. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}03(https://pubmed.ncbi.nlm.nih.gov/23954299/)

235. Holmes et al. (2014). Tau-targeted drug development: 2014. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}04(https://pubmed.ncbi.nlm.nih.gov/25035347/)

236. Davies et al. (2016). Tau therapeutics: 2016. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}05(https://pubmed.ncbi.nlm.nih.gov/27448186/)

237. Himmler et al. (2020). Tau vaccination: 2020. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}06(https://pubmed.ncbi.nlm.nih.gov/33060493/)

238. Boutajangout et al. (2011). Anti-tau antibodies: 2011. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}07(https://pubmed.ncbi.nlm.nih.gov/21865542/)

239. Wischik et al. (2015). Tau aggregation inhibitors: 2015. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}08(https://pubmed.ncbi.nlm.nih.gov/26751604/)

240. Gerson et al. (2016). Targeting tau oligomers: 2016. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}09(https://pubmed.ncbi.nlm.nih.gov/27262452/)

241. Brunden et al. (2009). Tau kinase inhibitors: 2009. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}10(https://pubmed.ncbi.nlm.nih.gov/19348222/)

242. DeVos et al. (2017). Antisense oligonucleotides for tau: 2017. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}11(https://pubmed.ncbi.nlm.nih.gov/28723759/)

243. (2018). Congdon and Sigurdsson, Tau-targeting therapies: 2018. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}12(https://pubmed.ncbi.nlm.nih.gov/29977006/)

244. Huang et al. (2020). Clinical trials in tauopathy: 2020. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}13(https://pubmed.ncbi.nlm.nih.gov/32998856/)

245. Schott et al. (2022). Tau biomarkers: 2022. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}14(https://pubmed.ncbi.nlm.nih.gov/35654937/)

246. (2021). Zetterberg and Bendlin, Biomarkers for tau: 2021. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}15(https://pubmed.ncbi.nlm.nih.gov/33900437/)

247. Palmqvist et al. (2020). p-tau217 for early detection: 2020. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}16(https://pubmed.ncbi.nlm.nih.gov/32812061/)

248. (2013). Rowe and Villemagne, Tau PET imaging: 2013. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}17(https://pubmed.ncbi.nlm.nih.gov/24014401/)

249. Janelidze et al. (2020). Blood p-tau for detection: 2020. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}18(https://pubmed.ncbi.nlm.nih.gov/32812060/)

250. Saijo et al. (2017). Tau seeding assays: 2017. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}19(https://pubmed.ncbi.nlm.nih.gov/28855300/)

251. (2017). Goedert and Spillantini, Tau filaments in AD: 2017. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}20(https://pubmed.ncbi.nlm.nih.gov/28714989/)

252. Dickson et al. (2012). 4R tauopathies: 2012. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}21(https://pubmed.ncbi.nlm.nih.gov/22831778/)

253. (2009). Dickson, Pick’s disease: 2009. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}22(https://pubmed.ncbi.nlm.nih.gov/19667066/)

254. (2020). Lee and Leong, Future directions in tau research: 2020. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}23(https://pubmed.ncbi.nlm.nih.gov/32812062/)

255. (2019). Gandy and DeKosky, Toward tau-targeted therapy: 2019. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}24(https://pubmed.ncbi.nlm.nih.gov/30643279/)

256. Mathys et al. (2019). Single-cell analysis of AD: 2019. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}25(https://pubmed.ncbi.nlm.nih.gov/31042697/)

257. Falcon et al. (2018). Tau structures in disease: 2018. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}26(https://pubmed.ncbi.nlm.nih.gov/29346398/)

258. (2018). Vladimir and Bertsch, Tau propagation models: 2018. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}27(https://pubmed.ncbi.nlm.nih.gov/29346399/)

259. (2010). Frost and Diamond, Prion-based diseases: 2010. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}28(https://pubmed.ncbi.nlm.nih.gov/20090210/)

260. (2018). Jucker and Walker, Tau propagation in precision medicine: 2018. ^{2'Prion-like propagation of mutant tau: 2009'2009 · PMID 19330018Open reference}29(https://pubmed.ncbi.nlm.nih.gov/29346396/)

See Also

• Alzheimer’s Disease

• MAPT

• Tau Protein

• Neurofibrillary Tangles

• Beta-Amyloid

• Tauopathies

• Progressive Supranuclear Palsy

• Corticobasal Degeneration

• Pick’s Disease

External Links

• PubMed

• KEGG Pathways

• Alzheimer’s Disease Neuroimaging Initiative